Eli Lilly
Eli Lilly predicts revenue growth in 2016
January 5, 2016Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales
Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Juan Luciano appointed to Eli Lilly board
December 16, 2015Medical Communications Eli Lilly
The board of directors of Eli Lilly has elected Juan Luciano as a new member, effective February 1 2016. Luciano …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
Lilly and Merck extend immuno-oncology collaboration
November 20, 2015Medical Communications, Research and Development Eli Lilly, Merck
Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
More positive CV data for Boehringer and Lilly’s Jardiance
September 21, 2015Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes
Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …
New Boehringer and Lilly type 2 diabetes treatment gets FDA nod
August 28, 2015Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes
The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …
Lilly defeats Teva in US court over Alimta patent
August 26, 2015Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer
Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …
Lilly and Boehringer launch biosimilar insulin in the UK
August 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks
August 21, 2015Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs
Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
UK pharma commits at least ‘one code breach a week’
February 18, 2015Medical Communications, Sales and Marketing ABPI, AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Novo Nordisk, PMCPA, Pfizer, code
Pharma companies commit unethical marketing practices on average more than once a week in the UK academic analysis has found. …
Lilly to market stomach cancer drug in Europe
December 22, 2014Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer
Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …
Latest content
Five Facts about cardiovascular disease
